A biomimetic hybrid nanoplatform for encapsulation and precisely controlled delivery of theranostic agents

Citations Over TimeTop 10% of 2015 papers

Abstract

Nanoparticles have demonstrated great potential for enhancing drug delivery. However, the low drug encapsulation efficiency at high drug-to-nanoparticle feeding ratios and minimal drug loading content in nanoparticle at any feeding ratios are major hurdles to their widespread applications. Here we report a robust eukaryotic cell-like hybrid nanoplatform (EukaCell) for encapsulation of theranostic agents (doxorubicin and indocyanine green). The EukaCell consists of a phospholipid membrane, a cytoskeleton-like mesoporous silica matrix and a nucleus-like fullerene core. At high drug-to-nanoparticle feeding ratios (for example, 1:0.5), the encapsulation efficiency and loading content can be improved by 58 and 21 times, respectively, compared with conventional silica nanoparticles. Moreover, release of the encapsulated drug can be precisely controlled via dosing near infrared laser irradiation. Ultimately, the ultra-high (up to ∼87%) loading content renders augmented anticancer capacity both in vitro and in vivo. Our EukaCell is valuable for drug delivery to fight against cancer and potentially other diseases.

Related Papers

• → Engineered Nanocarriers of Doxorubicin: A Current Update(2008)92 cited
• → Pluronic polymer capped biocompatible mesoporous silica nanocarriers(2013)62 cited
• → Sugar-conjugated dendritic mesoporous silica nanoparticles as pH-responsive nanocarriers for tumor targeting and controlled release of deferasirox(2019)59 cited
• → Anti-GPC1-modified mesoporous silica nanoparticles as nanocarriers for combination therapy and targeting of PANC-1 cells(2021)12 cited
• → Cancer Treatment: Biocompatible, Uniform, and Redispersible Mesoporous Silica Nanoparticles for Cancer‐Targeted Drug Delivery In Vivo (Adv. Funct. Mater. 17/2014)(2014)12 cited